We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Oncolytics Biotech has received clearance from the FDA to begin a Phase I/II
clinical trial to investigate the use of Reolysin to treat patients with recurrent
malignant gliomas.
RegeneRx Biopharmaceuticals is clear to begin its third Phase II clinical trial
to test its drug, Thymosin beta 4 (TB4), for the treatment of patients with
epidermolysis bullosa (EB), the company said.
Spectrum Pharmaceuticals has announced that data from a 50-patient randomized
Phase III clinical trial on satraplatin as first-line chemotherapy for hormone-refractory
prostate cancer has been published in the peer-reviewed journal Oncology.
Tercica has submitted a new drug application in the electronic common technical
document format to the FDA to market Increlex, recombinant human Insulin-like
Growth Factor-1 (rhIGF-1), for the long term treatment of growth failure in
children with a severe form of primary IGF-1 deficiency (Primary IGFD).
Pharmacopeia Drug Discovery and Celgene have announced the nomination for
development of a compound resulting from the ongoing collaboration between
the two companies.
Medidata Solutions, a global electronic clinical data management solutions
provider managing trials in 39 countries, and Icon Clinical Research, a full-service
global clinical research organization providing a comprehensive range of services
in Phase I-IV clinical trials, has announced a formal partnership to expand
Icon's global data management capabilities as a certified Medidata RAVE implementation
and services partner.